bioAffinity Inks Federal Distribution Deal for CyPath Lung with AvMEDICAL
BIAF sits 23% above its 52-week low of $0.325.
Summary
bioAffinity Technologies has signed a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business, to bring CyPath Lung into the federal healthcare market. The agreement is nationwide in scope. AvMEDICAL's government contracting expertise and IDIQ contract access open a new channel to the VA and other agencies. This expands commercial reach for the lung cancer diagnostic at a time when the company faces a going concern warning and Nasdaq delisting notice. The deal could accelerate adoption among veterans, a high-risk population for lung cancer. No financial terms were disclosed, but the partnership adds a credible federal sales pathway.
At the time of this announcement, BIAF was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.33 to $13.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.